Skin Longevity Needs Evidence, Not Hype

The language of longevity has rapidly entered medicine, wellness, and consumer culture. In dermatology, we increasingly hear about “skinspan,” biological skin age, senolytics, epigenetic reprogramming, regenerative treatments, and products said to make skin function and appear younger.¹ These concepts are scientifically intriguing, but they are also being commercialized faster than they are being clinically validated.

Dermatology is embracing skin longevity as a new field; however, we must pause to determine what the term means and what evidence should be required to support it.

The underlying science deserves serious attention. Many biological processes associated with aging are evident in aging skin, including cellular senescence, mitochondrial dysfunction, stem cell exhaustion, extracellular matrix deterioration, genomic instability, and altered intercellular communication.² The skin may also offer a uniquely accessible organ for studying biological aging through imaging, biomarker analysis, and minimally invasive sampling. These characteristics position the skin as both a manifestation of aging and a potential window into broader physiological aging of humans.

However, biological plausibility is not clinical proof.

What does it mean to extend skin longevity? Does it mean fewer wrinkles, more even pigmentation, preserved barrier function, reduced skin fragility, improved wound healing, lower cancer risk, or sustained immune competence? These are not interchangeable outcomes. A product that temporarily improves hydration or appearance may be useful, but that does not demonstrate that it has slowed biological aging or extended cutaneous health span.

The same caution applies to biomarkers. A treatment may alter gene expression, reduce a marker associated with cellular senescence, or produce a favorable epigenetic signal, yet a change in a laboratory marker does not necessarily translate into improved skin function, reduced disease, or better long-term health. Current frameworks for aging biomarkers emphasize the need to demonstrate analytical validity, biological relevance, responsiveness to intervention, and an association with meaningful health outcomes.³ We should not confuse target engagement with clinical efficacy, biomarker movement with health span, or youthful appearance with healthier skin.

Consider topical rapamycin. A small exploratory randomized study reported changes in senescence-associated markers and certain clinical and histologic features of aging skin.⁴ The findings were provocative and worthy of further investigation, but they do not establish rapamycin as a proven skin-longevity treatment. Larger studies, standardized outcomes, longer follow-up, and careful safety evaluation are needed before such approaches can be incorporated into routine practice.

Other interventions are promoted with even less clinical evidence. Exosomes, stem cell–derived products, peptides, supplements, and personalized biological-age tests are increasingly marketed using the vocabulary of regeneration and longevity. In some cases, the terminology conveys a level of scientific maturity that the supporting evidence does not yet warrant. The FDA has cautioned that misleading claims surround regenerative medicine products and states that there are currently no FDA-approved exosome products.⁵

This does not mean dermatology should dismiss longevity science. It means we should lead it responsibly.

Dermatology already has interventions that help preserve skin health over time. Photoprotection is a clear example. In a randomized clinical trial, participants assigned to daily sunscreen use experienced less progression of clinical skin aging over 4.5 years than those assigned to discretionary sunscreen use.⁶ This is meaningful evidence tied to a defined intervention and a clinically assessable outcome. We should apply similarly rigorous standards to emerging longevity claims.

An evidence-based framework for skin longevity should require several elements: a clear definition of the intended outcome, a plausible and measurable biological target, evidence of target engagement in human skin, validated clinical or functional end points, durable benefit, acceptable safety, and independent replication. Studies should also include diverse ages, skin types, ethnicities, and patterns of intrinsic and environmentally driven aging. In addition, the results of the studies should undergo rigorous peer review and publication so dermatology providers can read, learn, assess, and decide how to implement the advances in their practice.

Most importantly, the field must define cutaneous health span in terms that extend beyond appearance. Preserving barrier integrity, resilience to injury, immune surveillance, wound-healing capacity, sensory function, and protection from malignancy may be more meaningful than counting wrinkles alone. Cosmetic/aesthetic improvement can be valuable to patients, but it should not automatically be relabeled as longevity medicine.

Dermatologists have an important role at this intersection of science, medicine, and consumer expectation. We should remain open to discoveries that may eventually alter the biology of skin aging; such advances are what make dermatology an exciting, dynamic specialty and one of the best careers. At the same time, we must challenge exaggerated claims, explain uncertainty honestly, and protect patients from interventions that have moved from hypothesis to marketing without passing through adequate clinical investigation.

Skin longevity is on a path to becoming a legitimate and consequential area of dermatology. For it to fully succeed, skin longevity must be built on clear definitions, validated outcomes, and reproducible scientific and clinical evidence, not on the appeal of the word longevity itself.

The appropriate response to this emerging field is neither reflexive dismissal nor premature enthusiasm. It is scientific rigor.

Disclosure: Dr Bunick leads a research laboratory at Yale School of Medicine investigating the molecular and biochemical functions of the human skin barrier, fibroblasts, keratins, wound healing, and dermatology therapeutics. He is also the medical chair of SkinFuture Forum, an educational conference (February 2027) aligned with the South Beach Symposium.

References

1. Wyles SP, Maredia HS, Ansaf RB, et al. Skinspan: a healthy longevity framework for skin aging. Mayo Clin Proc. 2025;100(11):1976-1991. doi:10.1016/j.mayocp.2025.07.027
2. He R, Sun M, Liu T, et al. Hallmarks of the aging skin microenvironment: components and mechanisms. J Cell Physiol. 2025;240(11):e70111. doi:10.1002/jcp.70111
3. Moqri M, Herzog C, Poganik JR, et al. Validation of biomarkers of aging. Nat Med. 2024;30(2):360-372. doi:10.1038/s41591-023-02784-9
4. Chung CL, Lawrence I, Hoffman M, et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. GeroScience. 2019;41(6):861-869. doi:10.1007/s11357-019-00113-y
5. Consumer alert on regenerative medicine products including stem cells and exosomes. FDA. Published July 22, 2020. Updated April 9, 2024. Accessed July 15, 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
6. Hughes MC, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med. 2013;158(11):781-790. doi:10.7326/0003-4819-158-11-201306040-00002